Real World Evidence and Epidemiology, GlaxoSmithKline, Uxbridge, Middlesex, UK.
Worldwide Research and Development, Pfizer, Target Sciences, Groton, CT, USA.
BMJ. 2019 Oct 8;367:l5367. doi: 10.1136/bmj.l5367.
To estimate the risk of acute myocardial infarction (AMI) or stroke in adults with non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
Matched cohort study.
Population based, electronic primary healthcare databases before 31 December 2015 from four European countries: Italy (n=1 542 672), Netherlands (n=2 225 925), Spain (n=5 488 397), and UK (n=12 695 046).
120 795 adults with a recorded diagnosis of NAFLD or NASH and no other liver diseases, matched at time of NAFLD diagnosis (index date) by age, sex, practice site, and visit, recorded at six months before or after the date of diagnosis, with up to 100 patients without NAFLD or NASH in the same database.
Primary outcome was incident fatal or non-fatal AMI and ischaemic or unspecified stroke. Hazard ratios were estimated using Cox models and pooled across databases by random effect meta-analyses.
120 795 patients with recorded NAFLD or NASH diagnoses were identified with mean follow-up 2.1-5.5 years. After adjustment for age and smoking the pooled hazard ratio for AMI was 1.17 (95% confidence interval 1.05 to 1.30; 1035 events in participants with NAFLD or NASH, 67 823 in matched controls). In a group with more complete data on risk factors (86 098 NAFLD and 4 664 988 matched controls), the hazard ratio for AMI after adjustment for systolic blood pressure, type 2 diabetes, total cholesterol level, statin use, and hypertension was 1.01 (0.91 to 1.12; 747 events in participants with NAFLD or NASH, 37 462 in matched controls). After adjustment for age and smoking status the pooled hazard ratio for stroke was 1.18 (1.11 to 1.24; 2187 events in participants with NAFLD or NASH, 134 001 in matched controls). In the group with more complete data on risk factors, the hazard ratio for stroke was 1.04 (0.99 to 1.09; 1666 events in participants with NAFLD, 83 882 in matched controls) after further adjustment for type 2 diabetes, systolic blood pressure, total cholesterol level, statin use, and hypertension.
The diagnosis of NAFLD in current routine care of 17.7 million patient appears not to be associated with AMI or stroke risk after adjustment for established cardiovascular risk factors. Cardiovascular risk assessment in adults with a diagnosis of NAFLD is important but should be done in the same way as for the general population.
评估非酒精性脂肪性肝病(NAFLD)或非酒精性脂肪性肝炎(NASH)患者发生急性心肌梗死(AMI)或中风的风险。
匹配队列研究。
基于人群,来自四个欧洲国家的电子初级医疗保健数据库:意大利(n=1542672)、荷兰(n=2225925)、西班牙(n=5488397)和英国(n=12695046)。
120795 名记录有 NAFLD 或 NASH 诊断且无其他肝脏疾病的成年人,按年龄、性别、实践地点和就诊时间在 NAFLD 诊断(索引日期)时进行匹配,在诊断前或后六个月记录,与数据库中相同数据库中多达 100 名无 NAFLD 或 NASH 的患者进行匹配。
主要结局是发生致命或非致命性 AMI 和缺血性或未特指性中风的事件。使用 Cox 模型估计风险比,并通过随机效应荟萃分析在数据库之间进行汇总。
共确定了 120795 名记录有 NAFLD 或 NASH 诊断的患者,平均随访时间为 2.1-5.5 年。调整年龄和吸烟因素后,AMI 的合并风险比为 1.17(95%置信区间 1.05 至 1.30;NAFLD 或 NASH 患者中有 1035 例事件,匹配对照组中有 67823 例)。在一个具有更完整危险因素数据的组中(86098 名 NAFLD 和 4664988 名匹配对照组),调整收缩压、2 型糖尿病、总胆固醇水平、他汀类药物使用和高血压后,AMI 的风险比为 1.01(91%至 1.12;NAFLD 或 NASH 患者中有 747 例事件,匹配对照组中有 37462 例)。调整年龄和吸烟状况后,NAFLD 或 NASH 患者中风的合并风险比为 1.18(1.11 至 1.24;NAFLD 或 NASH 患者中有 2187 例事件,匹配对照组中有 134001 例)。在具有更完整危险因素数据的组中,进一步调整 2 型糖尿病、收缩压、总胆固醇水平、他汀类药物使用和高血压后,NAFLD 患者中风的风险比为 1.04(99%至 1.09;NAFLD 患者中有 1666 例事件,匹配对照组中有 83882 例)。
在当前对 1770 万患者的常规护理中诊断为 NAFLD 似乎与 AMI 或中风风险无关,在调整既定心血管危险因素后。对诊断为 NAFLD 的成年人进行心血管风险评估很重要,但应与一般人群相同的方式进行。